CIMPLE Explorer
  • Reviews
0 search results
English
http://fullfact.org/health/lung-cancer-drug-brexit/(permalink)
Author: full-fact
Factors
veracity
not verifiable
language
English
Date published
2021-05-11
Entities
OsimertinibDaily ExpressEuropean CommissionMatt HancockMutationEuropean Medicines AgencySwitzerlandSingaporeBrexitSocial mediaCanadaAustraliaCancerEuropean UnionUnited KingdomBrazilFull FactSmall-cell carcinomaOrbis InternationalSubgroupNon-small-cell lung carcinoma

Claims (1)

  • Osimertinib (the lung cancer medication) has been licensed in the EU for use since 2016.

The data contained in CIMPLE Explorer comes from CIMPLE Knowledge Base. CIMPLE Explorer has been developed at EURECOM.

CIMPLE Explorer
English
ReviewsClaim-review